Zelira Therapeutics Limited Stock Net Income
| ZLDAF Stock | USD 0.23 0.00 0.00% |
Fundamental analysis of Zelira Therapeutics allows traders to better anticipate movements in Zelira Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Zelira |
Zelira Therapeutics Limited OTC Stock Net Income Analysis
Zelira Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Zelira Therapeutics Net Income | (11.95 M) |
Most of Zelira Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zelira Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Zelira Therapeutics Limited reported net income of (11.95 Million). This is 103.5% lower than that of the Healthcare sector and 117.05% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.09% higher than that of the company.
Zelira Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zelira Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Zelira Therapeutics could also be used in its relative valuation, which is a method of valuing Zelira Therapeutics by comparing valuation metrics of similar companies.Zelira Therapeutics is currently under evaluation in net income category among its peers.
Zelira Fundamentals
| Return On Equity | -0.34 | |||
| Return On Asset | -0.21 | |||
| Operating Margin | (8.57) % | |||
| Current Valuation | 4.97 M | |||
| Shares Outstanding | 9.58 M | |||
| Shares Owned By Insiders | 44.26 % | |||
| Price To Earning | 20.00 X | |||
| Price To Book | 0.29 X | |||
| Price To Sales | 4.37 X | |||
| Revenue | 1.54 M | |||
| Gross Profit | 601.57 K | |||
| EBITDA | (11.77 M) | |||
| Net Income | (11.95 M) | |||
| Cash And Equivalents | 2.75 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 500.91 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.12 X | |||
| Book Value Per Share | 3.68 X | |||
| Cash Flow From Operations | (9.43 M) | |||
| Earnings Per Share | (1.05) X | |||
| Number Of Employees | 11 | |||
| Beta | 1.35 | |||
| Market Capitalization | 7.98 M | |||
| Total Asset | 37.7 M | |||
| Z Score | 9.0 | |||
| Net Asset | 37.7 M |
About Zelira Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zelira Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zelira Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zelira Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Zelira OTC Stock
Zelira Therapeutics financial ratios help investors to determine whether Zelira OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zelira with respect to the benefits of owning Zelira Therapeutics security.